secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2024-10-02T23:59:59+00:00
Accession:  0001213900-24-084337
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERo Therapeutics names new CFO and CDO, reprices options to $0.10
------------------------------------------------------------------

- Al Kucharchuk appointed CFO effective Oct 1, 2024; receives 500K stock options vesting over 12 months, monthly consulting fee $16K.
- Kristen Pierce appointed CDO effective Oct 1, 2024; receives 200K options vesting over 24 months (50% accelerated on FDA IND acceptance), $30K/mo fee.
- Chris Ehrlich named Interim CEO; receives 2.8M options vesting 50% on IND and 50% on $1.5M financing, $30K/mo fee.
- All outstanding options with exercise price >$0.10 repriced to $0.10 per share under 2024 Equity Incentive Plan.
- Brian Atwood (ex-CEO) and Charles Carter (ex-CFO) enter consulting agreements; Atwood forfeits 1.33M options, Carter forfeits 495K options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024084337/0001213900-24-084337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024084337/ea0216216-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-084337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer